Literature DB >> 9322522

Utility of hepatic iron index in American patients with hereditary hemochromatosis: a multicenter study.

K V Kowdley1, T D Trainer, J R Saltzman, M Pedrosa, E L Krawitt, T A Knox, K Susskind, D Pratt, H L Bonkovsky, N D Grace, M M Kaplan.   

Abstract

BACKGROUND & AIMS: A hepatic iron index (hepatic iron concentration divided by age) of more than 1.9 has been proposed as useful to identify patients with homozygous hereditary hemochromatosis (HHC). There are limited data on the diagnostic use of the hepatic iron index in patients with HHC in the United States. This study evaluated the hepatic iron index in the diagnosis of HHC in a multicenter U.S. study.
METHODS: Hepatic iron concentration was measured in 509 patients undergoing liver biopsy. The diagnosis of HHC was made using clinical, biochemical, and histopathologic criteria.
RESULTS: Fifty-five patients met criteria for HHC; hepatic iron index was > 1.9 in 51 of 55 (93%) patients with HHC but in none of 454 patients with other liver diseases; hepatic iron concentration was > 71 mumol/g dry weight in 54 of 55 patients with HHC but only 1 of the other 454 patients.
CONCLUSIONS: A hepatic iron index of > or = 1.9 can identify most U.S. patients with HHC but is < or = 1.9 in 7%. A "threshold" hepatic iron concentration of 71 mumol/g can almost always distinguish patients with HHC from patients with other liver diseases and may be a useful adjunct to the hepatic iron index in the diagnosis of HHC in the diverse U.S. population.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9322522     DOI: 10.1053/gast.1997.v113.pm9322522

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  8 in total

1.  [Hereditary hemochromatosis, alpha-1-antitrypsin deficiency and Wilson's disease. Pathogenesis, clinical findings and pathways to diagnosis].

Authors:  H Zhou; H-P Fischer
Journal:  Pathologe       Date:  2008-02       Impact factor: 1.011

2.  Convergence of hepcidin deficiency, systemic iron overloading, heme accumulation, and REV-ERBα/β activation in aryl hydrocarbon receptor-elicited hepatotoxicity.

Authors:  Kelly A Fader; Rance Nault; Mathew P Kirby; Gena Markous; Jason Matthews; Timothy R Zacharewski
Journal:  Toxicol Appl Pharmacol       Date:  2017-02-16       Impact factor: 4.219

3.  Iron overload: accuracy of in-phase and out-of-phase MRI as a quick method to evaluate liver iron load in haematological malignancies and chronic liver disease.

Authors:  J M Virtanen; T K Pudas; J A Ratilainen; J P Saunavaara; M E Komu; R K Parkkola
Journal:  Br J Radiol       Date:  2011-03-08       Impact factor: 3.039

Review 4.  Iron overload, hematopoietic cell transplantation, and graft-versus-host disease.

Authors:  H Joachim Deeg; Emily Spaulding; Howard M Shulman
Journal:  Leuk Lymphoma       Date:  2009-10

5.  Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors:  Bruce R Bacon; Paul C Adams; Kris V Kowdley; Lawrie W Powell; Anthony S Tavill
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

6.  Serum or plasma ferritin concentration as an index of iron deficiency and overload.

Authors:  Maria Nieves Garcia-Casal; Sant-Rayn Pasricha; Ricardo X Martinez; Lucero Lopez-Perez; Juan Pablo Peña-Rosas
Journal:  Cochrane Database Syst Rev       Date:  2021-05-24

7.  Vibration Controlled Transient Elastography (Fibroscan®) in sickle cell liver disease - could we strike while the liver is hard?

Authors:  Gil Ben Yakov; Disha Sharma; Hawwa Alao; Pallavi Surana; Devika Kapuria; Ohad Etzion; Matthew M Hsieh; John F Tisdale; Courtney D Fitzhugh; David E Kleiner; Elliot B Levy; Richard Chang; Elenita Rivera; Amy Huang; Christopher Koh; Theo Heller
Journal:  Br J Haematol       Date:  2019-06-19       Impact factor: 8.615

8.  The transplant iron score as a predictor of stem cell transplant survival.

Authors:  Jonathan A Storey; Rebecca F Connor; Zachary T Lewis; David Hurd; Gregory Pomper; Yi K Keung; Manisha Grover; James Lovato; Suzy V Torti; Frank M Torti; István Molnár
Journal:  J Hematol Oncol       Date:  2009-10-24       Impact factor: 17.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.